Nuochengjianhua's management said in today's interim results conference call that with the increase in drug sales and the BD cooperation milestone revenue expected to be achieved in the second half of the year, the company is very confident that it will maintain profit throughout 2026, and it is expected that the annual earnings per share will be higher than the level of the first half of the year. Yesterday evening's semi-annual report showed that Nuochengjianhua achieved net profit of 240 million yuan in the first half of the year, turning a year-on-year loss into a profit. At the same time, diluted earnings per share were 0.14 yuan during the reporting period.

Nuochengjianhua's management said in today's interim results conference call that with the increase in drug sales and the BD cooperation milestone revenue expected to be achieved in the second half of the year, the company is very confident that it will maintain profit throughout 2026, and it is expected that the annual earnings per share will be higher than the level of the first half of the year. Yesterday evening's semi-annual report showed that Nuochengjianhua achieved net profit of 240 million yuan in the first half of the year, turning a year-on-year loss into a profit. At the same time, diluted earnings per share were 0.14 yuan during the reporting period.